|
Type of Company:
Type:
|
Company
|
Ownership: |
Privately Held (Funded) |
Company Size: |
25 Employees In BC (25 Total)
25 In BC (25 Total)
|
Year Founded: |
2006 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
Aquinox, AQX-1125, SHIP1
|
Profile Views: |
2,487 Company Profile Views |
|
|
We are the world leaders in the discovery and development of novel, first-in-class, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase ("SHIP1") for the treatment of inflammatory disease.
Our lead clinical candidate, AQX-1125, is a highly active and selective small molecule allosteric activator of SHIP1 suitable for once-daily oral dosing as a pill. AQX-1125 is currently being investigated in two Phase II clinical trials that we anticipate completing in Q4 2014.
AQX-1125 is our lead candidate from our most advanced research program, our SHIP1 activator program, and has demonstrated broad anti-inflammatory activity both in vitro and in vivo.
AQX-1125 possesses many desirable drug-like properties and has generated promising clinical data.
We are now evaluating several closely related analogs that have unique properties for different routes of administration and we are advancing these follow-on products into IND-enabling studies.
|
|
|
Date |
Type |
Amount |
Investors |
Jun 17, 2010 |
Series B |
$25 Million CAD |
Led by Ventures West Capital. New investor Pfizer Venture Investments (PVI) participated in the financing along with all other existing investors: Johnson & Johnson Development Corporation, Baker Brothers Investments and BC Advantage Funds (VCC) Ltd. |
Apr 3, 2013 |
Series C |
$18 Million CAD |
Series C financing led by Johnson & Johnson Development Corporation. New investor Augment Investments Ltd. participated in the financing along with existing investors: Pfizer Venture Investments, Ventures West Capital, and Baker Brothers Investments. |
Date |
Type |
Amount |
Investors |
Jun 17, 2010 |
Series B |
$25M CAD |
Led by Ventures West Capital. New investor Pfizer Venture Investments (PVI) participated in the financing along with all other existing investors: Johnson & Johnson Development Corporation, Baker Brothers Investments and BC Advantage Funds (VCC) Ltd. |
Apr 3, 2013 |
Series C |
$18M CAD |
Series C financing led by Johnson & Johnson Development Corporation. New investor Augment Investments Ltd. participated in the financing along with existing investors: Pfizer Venture Investments, Ventures West Capital, and Baker Brothers Investments. |
|
|
Want More Aquinox Pharmaceuticals News? 1 2 3
|
Next »
|
|
|
|
|
Aug 13, 2019
|
Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction, Head Office Moves to Seattle
|
Aug 8, 2019
|
Vancouver-based Aquinox Pharmaceuticals to Acquire Neoleukin Therapeutics to Create $65 Million Capitalized Company
|
Aug 20, 2018
|
Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results
|
Jun 28, 2018
|
Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome
|
Jun 13, 2018
|
Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial
|
May 11, 2018
|
Aquinox and Astellas Announce Licensing Agreement for Aquinox's Lead Drug Candidate in Asia-Pacific worth Potential $100M+
|
Feb 13, 2018
|
Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
|
Dec 28, 2017
|
Aquinox Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
|
Dec 19, 2017
|
Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations
|
Nov 28, 2017
|
Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
|
|
1 - 10 of 38 results
|
|
 |
|
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|